Nov 19O6.31H6.57L6.09C6.12Vol739.1k
Eupraxia Pharmaceuticals Inc stock is traded at $6.12, with a volume of 739,057. It is down -1.45% in the last 24 hours and down -11.94% over the past month. Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Previous Close:
$6.21
Open:
$6.31
24h Volume:
739,057
Relative Volume:
0.96
Market Cap:
$411.68M
Revenue:
-
Net Income/Loss:
-$44.47M
P/E Ratio:
-
EPS:
-$1.02
Net Cash Flow:
-$33.50M
1W Performance:
-21.64%
1M Performance:
-11.94%
6M Performance:
-2.70%
1Y Performance:
-1.29%
1-Day Range:
$6.09$6.57
1-Week Range:
$6.09$8.26
52-Week Range:
$5.63$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS